High serum levels of both sCTLA-4 and sPD-L1 identified patients with NSCLC r or gastrointestinal cancer less likely to respond to anti-PD-1 therapy, emphasizing the importance of this largely overlooked alternatively spliced isoform of CTLA-4 [89, 90]. Here, CTLA4 is linked to non-small cell lung carcinoma.